Correlation of biochemical markers and HCV RNA titers with fibrosis stages and grades in chronic HCV-3a patients

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 7, 2014, Pages 788-794

  Shahid, Muhammad ^a   Idrees, Muhammad ^a   Nasir, Bilal ^b   Raja, Arsalan J ^b   Raza, Syed M ^a   Amin, Iram ^a   Rasul, Afza ^c   Tayyab, Ghias U ^b  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

^b Ameeruddin Medical College PGMI Lahore General Hospital M Phil Stud   (Pakistan)

^c UNIVERSITY OF LAHORE   (Pakistan)

Author keywords

Alanine aminotransferase; Alkaline phosphatase; Aspartate aminotransferase; Chronic hepatitis C; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOCHEMICAL MARKER; VIRUS RNA; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC DISEASE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS SUBTYPE 3A; HUMAN; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; BIOPSY; BLOOD; CLINICAL TRIAL; DRUG MONITORING; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER; LIVER CIRRHOSIS; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; VIROLOGY; YOUNG ADULT;

ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BIOLOGICAL MARKERS; BIOPSY; DRUG MONITORING; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84902259352     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000109     Document Type: Article

References (57)

1. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46.
2. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26:34S-38S.
3. Smith MW, Yue ZN, Korth MJ, Do HA, Boix L, Fausto N, et al. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology 2003; 38:1458-1467.
4. Hamid S, Umar M, Alam A, Siddiqui A, Qureshi H, Butt J. PSG consensus statement on management of hepatitis C virus infection. J Pak Med Assoc 2004; 54:146-150.
5. Aslam M, Aslam J. Seroprevalence of the antibody to hepatitis C in select groups in the Punjab region of Pakistan. J Clin Gastroenterol 2001; 33:407-411.
6. Muhammad N, Jan MA. Frequency of hepatitis 'C' in Buner, NWFP. J Coll Physicians Surg Pak 2005; 15:11-14.
7. Akhtar S, Moatter T. Multilevel modeling of intra-household spread of hepatitis C virus infection, Karachi, Pakistan. Am J Trop Med Hyg 2007; 76:446-449.
8. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13:223-235.
9. Idrees M, Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis 2008; 8:69.
10. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers R, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3:8.
11. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
12. Tassopoulos NC, Papatheodoridis GV, Katsoulidou A, Delladetsima JK, Sypsa V, Touloumi G, et al. Factors associated with severity and disease progression in chronic hepatitis C. Hepatogastroenterology 1998; 45:1678-1683.
13. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33:1358-1364.
14. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32:477-481.
15. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008; 47:789-798.
16. Mueller S, Millonig G, Sarovska L, Friedrich S, Reimann FM, Pritsch M, et al. Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol 2010; 16:966-972.
17. Naveau S, Gaude G, Asnacios A, Agostini H, Abella A, Barri-Ova N, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49:97-105.
18. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46:32-36.
19. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96:3142-3146.
20. Cale s P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet M-C, Konate A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42:1373-1381.
21. Forns X, Ampurdane s S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36:986-992.
22. Leroy V, Hilleret M-N, Sturm N, Trocme C, Renversez J-C, Faure P, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46:775-782.
23. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
24. Husa P. Liver biopsy in chronic hepatitis virus C infection-unnecessary, useful or useless? J Intern Med 2002; 48:1004-1006.
25. Zechini B, Pasquazzi C, Aceti A. Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: the role of serum aspartate transaminase in the evaluation of disease progression. Eur J Gastroenterol Hepatol 2004; 16:891-896.
26. Adinolfi LE, Utili R, Andreana A, Tripodi MF, Marracino M, Gambardella M, et al. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci 2001; 46:1677-1683.
27. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26:1393-1398.
28. Anand B-S, Velez M. Assessment of correlation between serum titers of hepatitis C virus and severity of liver disease. World J Gastroenterol 2004; 10:2409-2411.
29. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36:S179-S184.
30. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20:15-20.
31. Idrees M. Development of an improved genotyping assay for the detection of hepatitis C virus genotypes and subtypes in Pakistan. J Virol Methods 2008; 150:50-56.
32. Bonino F, Oliveri F, Colombatto P, Coco B, Mura D, Realdi G, Brunetto MR. Treatment of patients with chronic hepatitis C and cirrhosis. J Hepatol 1999; 31 (Suppl 1):197-200.
33. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26:122S-127S.
34. Kaserer K, Fiedler R, Steindl P, Müller CH,Wrba F, Ferenci P. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. Histopathology 1998; 32:454-461.
35. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
36. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
37. Bedossa P, Darge re D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449-1457.
38. Raja NS, Janjua KA. Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect 2008; 41:4-8.
39. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996; 23:695-699.
40. Ahmad W, Ijaz B, Javed FT, Jahan S, Shahid I, Khan FM, Hassan S. HCV genotype distribution and possible transmission risks in Lahore, Pakistan. World J Gastroenterol 2010; 16:4321-4328.
41. Idrees M, Rafique S, Rehman I, Akbar H, Yousaf M-Z, Butt S, et al. Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gastroenterol 2009; 15:5080-5085.
42. Mendes LSC, Nita ME, Ono-Nita SK, Mello ES, da Silva LC, Alves VAF, Carrilho FJ. Prognostic factors for progression of liver structural lesions in chronic hepatitis C patients. World J Gastroenterol 2008; 14:2522-2528.
43. Ramalho F, Costa A, Pires A, Cabrita P, Serejo F, Correia AP, et al. Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C. Dig Dis Sci 2000; 45:182-187.
44. Reedy DW, Loo AT, Levine RA. AST/ALT ratio or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998; 43: 2156-2159.
45. Liu P, Li Y, Sun CM. Correlations of serum hepatitis C virus RNA and alanine transaminase with liver histopathological changes in patients with chronic hepatitis C. Lab Medicine 2009; 40:167-169.
46. Cahen DL, van Leeuwen DJ, ten Kate FJ, Blok AP, Oosting J, Chamuleau RA. Do serum ALAT values reflect the inflammatory activity in the liver of patients with chronic viral hepatitis? Liver 1996; 16:105-109.
47. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075.
48. Javed F, Ijaz B, AhmadW, Jahan S, Khaliq S, Hassan S. Correlation of serum HCV titer, ALP and bilirubin levels with liver fibrosis stage. IJAVMS 2010; 4:56-62.
49. Wiwanitkit V. High serum alkaline phosphatase levels, a study in 181 Thai adult hospitalized patients. BMC Fam Pract 2001; 2:2.
50. Saif MW, Alexander D, Wicox CM. Serum alkaline phosphatase level as a prognostic tool in colorectal cancer: a study of 105 patients. J Appl Res 2005; 5:88-95.
51. Azzari C, Resti M, Moriondo M, Ferrari R, Lionetti P, Vierucci A. Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection. Blood 2000; 96:2045-2048.
52. Lee YS, Yoon SK, Chung ES, Bae SH, Choi JY, Han JY, et al. The relationship of histologic activity to serum ALT, HCV genotype and HCV RNA titers in chronic hepatitis C. J Korean Med Sci 2001; 16:585-591.
53. Kao JH, Lai MY, Chen PJ, Hwang LH, Chen W, Chen DS. Clinical significance of serum hepatitis C virus titers in patients with chronic type C hepatitis. Am J Gastroenterol 1996; 91:506-510.
54. Zeuzem S, Franke A, Lee JH, Herrmann G, Ruster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology 1996; 24:1003-1009.
55. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993; 18:16-20.
56. Fanning L, Kenny E, Sheehan M, Cannon B,Whelton M, O'Connell J, et al. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology 1999; 29:904-907.
57. Gretch D, Corey L, Wilson J, dela Rosa C, Willson R, Carithers R Jr, et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J Infect Dis 1994; 169:1219-1225.